Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
RANKL
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Not available
Cancer name
Non-Small Cell Lung Cancer
Cancer site
qRT-PCR,Western blot
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
The current findings indicate that RANKL contributes to DDP resistance in NSCLC and may represent a novel therapeutic target in this malignancy
Tissue resource
non-small cell lung cancer cell lines A549
non-small cell lung cancer cisplatin-resistant cell lines A549/DDP
Experiment
None
Institute
the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.